Plus   Neg

Stock Alert: Bellerophon Therapeutics Soars 95%

Bellerophon Therapeutics, Inc. (BLPH) shares are currently gaining 95% on Tuesday morning after the clinical-stage biotherapeutics company reported positive results from its study for treatment of pulmonary hypertension.

BLPH is currently trading at $6.70, up $3.27 or 95.34%, on the Nasdaq, on a volume of 4.7 million shares, compared to its average volume of 53 thousand.

Bellerophon Tuesday announced positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study of INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis.

The results showed that acute treatment with INOpulse provided statistically and clinically significant improvements in hemodynamic parameters.

The study found that pulmonary vascular resistance reduced by 21%, with increased benefit on dose escalation from iNO30 to iNO45.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) expects that its first-quarter operating profit will increase about 2.73 percent from last year, sales will also increase 4.98 percent. JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered.
Follow RTT